Fifty high-end projects signed with Daxing district
On Sept 27, 2018, the Fourth Collaborative Innovation Workshop for National High-tech Zone Biomedicine Industry Clusters was hosted in Daxing district. Over 50 high-end projects, including Huoju Guokang (Daxing) International “Medical Valley”, a joint educational program with Stanford University, and a Sunbio Tech 3D printing project, have signed agreements with the Daxing Biomedicine Industrial Base, with a total investment in excess of RMB 10 billion. By the year 2025, Daxing aims to cultivate a medicine and healthcare cluster worth one hundred billion yuan.
“As the growth pattern of the Chinese economy has shifted from high-growth-rate to high-quality, we are in a transitioning period to realize economic restructuring and change of growth momentum,” said Tian Dexiang, head of the Daxing Biomedicine Industrial Base Management Committee, adding “The launch of 50 high-end projects will equip the industrial base with world-class technical and professional teams, facilitating the development of a 100-billion medicine and healthcare industrial cluster in Daxing.” The 50 projects fall evenly into the five categories of platforms, international cooperation, medical instruments, biomedicine, and industrial funds.
Beijing is positioned to be a national tech and innovation center. The Daxing Biomedicine Industrial Base, as a designated area for the biomedicine industry, is destined to be an important frontier of high-end medicine and healthcare manufacturing, as well as high-tech services. Now, the industrial base has established a whole industrial-chain plan covering biomedicine, traditional Chinese medicine, innovative chemical medicine, medical instruments, and medical healthcare. It is supported by national-level pharmaceutical authorities and medicine R&D institutions such as the National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences, and the China Academy of Chinese Medical Sciences, as well as industrial leaders such as Tongrengtang, Yiling Pharmaceutical, and Zhongguancun Medical Instrument Park. The total investment exceeds RMB 50 billion. “The next round of competition for regional advantages should be achieved through sound top-level planning of the park, brand advantages of industrial leaders, innovation capacity of small-and-medium-sized enterprises, and a high-quality industrial environment,” said Tian.
In addition to the signing of these 50 high-end projects, the Beijing Jianxing Medical and Healthcare Industrial Equity Fund, an academician and expert station, and a training base of Beijing University of Chemical Technology were inaugurated in the industrial base.